Brief: Leveragen Collaboration With Daiichi Sankyo To Support Development Of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms
18/03/2026 12:09
March 18 (Reuters) - Daiichi Sankyo Co Ltd 4568.T: LEVERAGEN: COLLABORATION WITH DAIICHI SANKYO TO SUPPORT DEVELOPMENT OF ADVANCED BIOLOGICS USING NEXT-GEN IN VIVO ANTIBODY DISCOVERY PLATFORMS Source text: ID:nBw7LyDCqa Further company coverage: 4568.T ((Reuters.Briefs@thomsonreuters.com;))